Table 1. Baseline characteristics of the ITT population of HIV-infected participants.

Characteristic	R3R group N = 51	R3C group N = 54	C3C group N = 48
Age category
5–17 months, n (%)	24 (47.1)	29 (53.7)	32 (66.7)
6–12 weeks, n (%)	27 (52.9)	25 (46.3)	16 (33.3)
Mean age at dose 1±SD
5–17 months, months	10.3 ± 3.4	9.7 ± 4.0	10.8 ± 3.8
6–12 weeks, weeks	7.6 ± 1.5	7.6 ± 1.6	7.5 ± 1.5
Mean age at HIV positive test ± SD
5–17 months, months	17.9 ± 7.5	22.4 ± 13.1	17.7 ± 12.3
6–12 weeks, months	9.1 ± 7.8	10.0 ± 8.8	15.6 ± 9.9
Both age categories, months	13.8 ± 8.8	17.1 ± 12.8	17.5 ± 11.6
Female sex, n (%)	19 (37.3)	34 (63.0)	22 (45.8)
Mean height-for-age z-score ± SD	—1.6 ± 1.1	—1.7 ± 1.5a	—1.6 ± 1.3
Mean weight-for-age z-score ± SD	—1.1 ± 1.2b	—1.4 ± 1.4	—1.1 ± 1.1
Mean Hb ± SD, g/dL	10.2 ± 1.7	10.3 ± 1.6	10.2 ± 1.7
Moderate anemia c , n (%)	4 (7.8)	3 (5.6)	2 (4.2)
Study center, n (%)
Agogo, Ghana	2 (3.9)	0 (0.0)	1 (2.1)
Bagamoyo, Tanzania	2 (3.9)	1 (1.9)	1 (2.1)
Kilifi, Kenya	0 (0.0)	2 (3.7)	2 (4.2)
Kintampo, Ghana	0 (0.0)	5 (9.3)	3 (6.3)
Kombewa, Kenya	8 (15.7)	5 (9.3)	6 (12.5)
Korogwe, Tanzania	1 (2.0)	2 (3.7)	0 (0.0)
Lambaréné, Gabon	0 (0.0)	0 (0.0)	1 (2.1)
Lilongwe, Malawi	3 (5.9)	9 (16.7)	6 (12.5)
Manhiça, Mozambique	11 (21.6)	12 (22.2)	14(29.2)
Nanoro, Burkina Faso	0 (0.0)	0 (0.0)	0 (0.0)
Siaya, Kenya	24 (47.1)	18 (33.3)	14(29.2)

ITT, intent-to-treat; R3R, group receiving 4 doses of RTS,S/AS01; R3C, group receiving 3 doses of RTS,S/AS01 plus 1 dose of comparator vaccine; C3C, group receiving 4 doses of comparator vaccine; N, number of participants in the ITT population of HIV-infected participants; n (%), number (percentage) of participants in a given category; SD, standard deviation; Hb, hemoglobin.

^aHeight-for-age z-score available for 52 participants in the R3C group.

^bWeight-for-age z-score available for 50 participants in the R3R group.

^cHb < 8g/dL.